

Gisele W B Colleoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5814891/publications.pdf>

Version: 2024-02-01

86
papers

2,252
citations

304368

22
h-index

223531

46
g-index

87
all docs

87
docs citations

87
times ranked

3481
citing authors

#	ARTICLE	IF	CITATIONS
1	International, evidence-based consensus diagnostic criteria for HHV-8 negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	0.6	381
2	Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor. <i>American Journal of Pathology</i> , 2001, 159, 411-415.	1.9	335
3	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
4	AT1C-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35). <i>American Journal of Pathology</i> , 2000, 156, 781-789.	1.9	168
5	Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. <i>Cancer Immunity</i> , 2008, 8, 2.	3.2	76
6	FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1189-1197.	2.0	65
7	Psychosocial adaptation and quality of life among Brazilian patients with different hematological malignancies. <i>Journal of Psychosomatic Research</i> , 2006, 60, 505-511.	1.2	54
8	SAGE analysis highlights the importance of p53, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. <i>Cancer Letters</i> , 2009, 278, 41-48.	3.2	51
9	Aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. <i>International Journal of Cancer</i> , 2009, 125, 1985-1991.	2.3	48
10	The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-4.	3.3	46
11	Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2004, 45, 2071-2078.	0.6	37
12	Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. <i>Haematologica</i> , 2008, 93, 791-792.	1.7	34
13	Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 195-212.	2.0	34
14	Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: A nested case-control study in a renal transplant cohort. <i>Leukemia and Lymphoma</i> , 2005, 46, 533-539.	0.6	32
15	A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly. <i>Oncotarget</i> , 2014, 5, 11813-11826.	0.8	32
16	Prognostic significance of vascular endothelial growth factor immunoreactivity in the context of adverse standard prognostic factors in multiple myeloma. <i>European Journal of Haematology</i> , 2004, 73, 311-317.	1.1	31
17	Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. <i>Cancer Letters</i> , 2017, 403, 206-215.	3.2	31
18	Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	30

#	ARTICLE	IF	CITATIONS
19	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	0.8	29
20	Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism. <i>Scientific Reports</i> , 2019, 9, 1056.	1.6	28
21	p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. <i>Cancer Letters</i> , 2005, 222, 247-254.	3.2	26
22	Angiomirs expression profiling in diffuse large B-Cell lymphoma. <i>Oncotarget</i> , 2016, 7, 4806-4816.	0.8	24
23	MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 191-195.	2.0	23
24	Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. <i>Brazilian Journal of Medical and Biological Research</i> , 2007, 40, 265-267.	0.7	23
25	Bilateral Central Retinal Vein Occlusion Associated with Multiple Myeloma. <i>Ophthalmologica</i> , 2004, 218, 283-287.	1.0	22
26	TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 1105-1110.	1.8	22
27	Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?. <i>European Journal of Haematology</i> , 2003, 70, 198-199.	1.1	21
28	Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2011, 6, e27707.	1.1	21
29	TGF β 2R2 Methylation Assessed by Quantitative-MSP in Multiple Myeloma Patients: An Independent Prognostic Marker. <i>Blood</i> , 2008, 112, 4475-4475.	0.6	21
30	Primary Breast Lymphoma: An Uncommon but Curable Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 149-151.	0.6	20
31	Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 269-282.	2.0	19
32	Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma. <i>Human Pathology</i> , 2002, 33, 496-502.	1.1	16
33	Cutaneous T-cell lymphoma with HTLV-I infection: clinical overlap with adult T-cell leukemia/lymphoma. <i>International Journal of Dermatology</i> , 2006, 45, 447-449.	0.5	15
34	Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2207-2214.	2.0	15
35	Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 597-604.	1.0	15
36	Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma. <i>Oncotarget</i> , 2017, 8, 114698-114709.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Post-Transplant Lymphoproliferative Disorders (PTLD) after Renal Transplantation: Management and Evolution of Seven Cases Among 1002 Renal Transplants in Sao Paulo, Brazil. <i>Leukemia and Lymphoma</i> , 2000, 39, 145-150.	0.6	13
38	Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 257-264.	0.6	13
39	Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. <i>Experimental Hematology</i> , 2009, 37, 446-449.	0.2	13
40	Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. <i>Histology and Histopathology</i> , 2009, 24, 991-7.	0.5	13
41	Impact of Highly Active Antiretroviral Therapy in the Treatment of HIV-Infected Patients with Systemic Non-Hodgkin's Lymphoma. <i>Acta Oncologica</i> , 2002, 41, 192-196.	0.8	12
42	An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. <i>BMC Cancer</i> , 2011, 11, 416.	1.1	12
43	Comparison of a Multiplex Reverse Transcriptase-Polymerase Chain Reaction for BCR-ABL to Fluorescence In Situ Hybridization, Southern Blotting, and Conventional Cytogenetics in the Monitoring of Patients With Ph1-Positive Leukemias. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 203-209.	2.1	10
44	Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. <i>Haematologica</i> , 2004, 89, 366-8.	1.7	10
45	Advances in the Treatment of Multiple Myeloma: The Role of Thalidomide. <i>Leukemia and Lymphoma</i> , 2003, 44, 291-298.	0.6	9
46	2-Chloro-deoxyadenosine Induces Durable Complete Remission in Castleman's Disease but may Accelerate its Transformation to Non-Hodgkin's Lymphoma. <i>Acta Oncologica</i> , 2003, 42, 784-787.	0.8	9
47	BCR-ABL Rearrangement in Adult T-cell Acute Lymphoblastic Leukemia. <i>American Journal of Hematology</i> , 1996, 53, 277-278.	2.0	8
48	Reciprocal Cdc25A and p27 Expression in B-Cell Non-Hodgkin Lymphomas. <i>Diagnostic Molecular Pathology</i> , 2003, 12, 128-132.	2.1	8
49	Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients. <i>Clinics</i> , 2011, 66, 1855-9.	0.6	8
50	Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2016, 6, e464-e464.	2.8	7
51	Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 66-69.	0.7	7
52	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1837-1839.	0.6	6
53	Possible Influence of Clinical Stage and Type of Treatment in the Persistence of Residual Circulating t(14;18)-Positive Cells in Follicular Lymphoma Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 539-545.	0.6	6
54	Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients?. <i>Leukemia and Lymphoma</i> , 2007, 48, 526-530.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1543-1549.	0.6	6
56	Serum free light chains and post-transplant lymphoproliferative disorder in patients with renal transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 2177-2180.	0.6	6
57	Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. <i>Acta Oncol</i> , 2004, 43, 215-216.	0.8	4
58	Proangiogenic cytokines produced by non-Hodgkin lymphoma tumor cells induce angiogenesis in infiltrated bone marrow samples. <i>Leukemia and Lymphoma</i> , 2009, 50, 1381-1383.	0.6	4
59	May critical molecular cross-talk between indoleamine 2,3-dioxygenase (IDO) and arginase during human aging be targets for immunosenescence control?. <i>Immunity and Ageing</i> , 2021, 18, 33.	1.8	4
60	Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression. <i>Brazilian Journal of Medical and Biological Research</i> , 2005, 38, 1609-1613.	0.7	3
61	Essential thrombocythemia after treatment of non-Hodgkin's lymphoma. <i>Leukemia Research</i> , 2007, 31, 1593-1595.	0.4	3
62	Comparative Expression of a Set of Genes to an Internal Housekeeping Control in CDNA Amplified and not Amplified by PolyAPCR in Non-Hodgkin's Lymphoma Samples Obtained From Fine-Needle Aspiration Cytology. <i>Diagnostic Molecular Pathology</i> , 2010, 19, 40-44.	2.1	3
63	Prognosis of Patients with Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PTLD-CNS) Treated with Immunosuppression Reduction, Intrathecal Chemotherapy and Whole-Brain Radiotherapy: An Analysis of 23 Patients in a Brazilian Cohort. <i>Blood</i> , 2015, 126, 3913-3913.	0.6	3
64	Granulocytic sarcoma presented as a reactivation of chronic myeloid leukemia after allogenic marrow transplantation. <i>Sao Paulo Medical Journal</i> , 1998, 116, 1689-1691.	0.4	2
65	Correlation Between Histological Subtype and Type of bcl-2/IgH Rearrangement in Follicular Lymphomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 331-338.	0.6	2
66	Poor Survival Predicted by MDM2 Oncoprotein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Wild-Type TP53 Gene. <i>Blood</i> , 2008, 112, 5269-5269.	0.6	2
67	Understanding myeloma cancer stem cells. <i>Immunotherapy</i> , 2013, 5, 1291-1294.	1.0	1
68	Is there any relationship between gene expression of tumor antigens and CD4+T cells in multiple myeloma?. <i>Immunotherapy</i> , 2014, 6, 569-575.	1.0	1
69	Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1. <i>Leukemia and Lymphoma</i> , 2014, 55, 1176-1180.	0.6	1
70	microRNA and Severity of Sickle Cell Anemia. <i>Blood</i> , 2018, 132, 3647-3647.	0.6	1
71	Multiple Myeloma Cancer Stem Cells: Immunophenotypic and Functional Characterization, Gene Expression Profiling and Therapeutic Targets. <i>Blood</i> , 2016, 128, 4434-4434.	0.6	1
72	Heat Shock Protein 70 Inhibitor, Alone or in Combination with Bortezomib, Prevented Plasmacytoma Development in Immunodeficient Mice Transplanted with Myeloma Cell Lines. <i>Blood</i> , 2016, 128, 5658-5658.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines. <i>Current Molecular Medicine</i> , 2019, 19, 112-119.	0.6	1
74	Multiple Myeloma Profile In Latin America: Clinical and Epidemiological Observational Study. <i>Blood</i> , 2013, 122, 5327-5327.	0.6	1
75	Relationship Between the Type of BCR-ABL Rearrangement and Bone Marrow Histopathological Features in Chronic Myeloid Leukemia. <i>Acta Oncol³gica</i> , 1997, 36, 313-315.	0.8	0
76	Clinical management of six cases of low-risk primary tonsillar non-Hodgkin's lymphoma. <i>Sao Paulo Medical Journal</i> , 1999, 117, 215-217.	0.4	0
77	Molecular analysis of gastric washings in the diagnosis and monitoring of gastric lymphomas. <i>Human Pathology</i> , 2004, 35, 582-586.	1.1	0
78	Tratamento de primeira linha no Mieloma M ^l tiplo. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2007, 29, .	0.7	0
79	Validation of International Staging System (ISS) for Multiple Myeloma: A Retrospective Analysis of 487 Patients at 8 Brazilian Centers.. <i>Blood</i> , 2005, 106, 5069-5069.	0.6	0
80	Expression of Cancer-Testis Antigens in Non-Hodgkin's Lymphomas. <i>Blood</i> , 2008, 112, 5281-5281.	0.6	0
81	Frequency and Prognostic Relevance of Cancer Testis Antigen 45 Expression in Multiple Myeloma. <i>Blood</i> , 2008, 112, 5134-5134.	0.6	0
82	Identification of New Upregulated Genes with Possible Relevance for Multiple Myeloma Tumorigenesis. <i>Blood</i> , 2008, 112, 2707-2707.	0.6	0
83	VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma. <i>Blood</i> , 2014, 124, 3022-3022.	0.6	0
84	Clinical Outcome of 96 Post-Transplant Lymphoproliferative Disease Patients in a Renal Transplant Cohort. <i>Blood</i> , 2015, 126, 5054-5054.	0.6	0
85	In Vitro JAK1/2 Inhibition, in Association with Bortezomib and Lenalidomide, Is Comparable with Bortezomib, Lenalidomide and Dexametasone: An Alternative for Multiple Myeloma Patients with JAK2 overexpression?. <i>Blood</i> , 2016, 128, 5663-5663.	0.6	0
86	Immunosenescence and Cancer. <i>Healthy Ageing and Longevity</i> , 2022, , 165-176.	0.2	0